Howard L, Heaphey L, Fleming C R, Lininger L, Steiger E
Division of Clinical Nutrition, Albany Medical Center, New York 12208.
JPEN J Parenter Enteral Nutr. 1991 Jul-Aug;15(4):384-93. doi: 10.1177/0148607191015004384.
The OASIS Registry started annual collection of longitudinal data on patients on home parenteral nutrition (HPN) in 1984. This report describes outcome profiles on 1594 HPN patients in seven disease categories. Analysis showed clinical outcome was principally a reflection of the underlying diagnosis. Patients with Crohn's disease, ischemic bowel disease, motility disorders, radiation enteritis, and congenital bowel dysfunction all had a fairly long-term clinical outcome, whereas those with active cancer and acquired immunodeficiency syndrome (AIDS) had a short-term outcome. The long-term group had a 3-year survival rate of 65 to 80%, they averaged 2.6 complications requiring hospitalization per year, and 49% experienced complete rehabilitation. The short-term group had a mean survival of 6 months; they averaged 4.6 complications per year and about 15% experienced complete rehabilitation. The registry data also indicated HPN was used for 19,700 patients in 1987 with therapy growth averaging about 8% per year. This growth was chiefly from new cancer patients. The number of new patients with long-term disorders in whom HPN was initiated appeared rather constant. We conclude that these clinical outcome assessments justify HPN for long-term patients, but the utility and appropriateness of HPN for the cancer and AIDS patients remains uncertain and requires further study. Medical, social, and fiscal aspects of HPN management in long-term and short-term patients appear to involve quite separate considerations.
OASIS注册中心于1984年开始每年收集接受家庭肠外营养(HPN)患者的纵向数据。本报告描述了7种疾病类别中1594例HPN患者的预后情况。分析表明,临床结果主要反映了潜在的诊断。患有克罗恩病、缺血性肠病、动力障碍、放射性肠炎和先天性肠功能障碍的患者都有相当长期的临床结果,而患有活动性癌症和获得性免疫缺陷综合征(AIDS)的患者则有短期结果。长期组的3年生存率为65%至80%,他们平均每年有2.6次需要住院治疗的并发症,49%的患者实现了完全康复。短期组的平均生存期为6个月;他们平均每年有4.6次并发症,约15%的患者实现了完全康复。注册中心的数据还表明,1987年有19700名患者接受了HPN治疗,治疗增长率平均约为每年8%。这种增长主要来自新的癌症患者。开始接受HPN治疗的患有长期疾病的新患者数量似乎相当稳定。我们得出结论,这些临床结果评估证明HPN对长期患者是合理的,但HPN对癌症和艾滋病患者的效用和适用性仍不确定,需要进一步研究。长期和短期患者HPN管理的医学、社会和财政方面似乎涉及相当不同的考虑因素。